GI Oncologist, researcher

Joined August 2020
not trying to get more credit. I am honored by having been both. nominated and selected for this award by @eaonc. Just going to note one of my key statements: A full professor who is EVER first author or presenter of new data on the podium missed out on a mentoring opportunity.
Congrats to 🌟 @jordanberlin5 for winning the @eaonc #Mentor of the Year Award! 👏👏👏 Well deserved!!!! He received a standing ovation!! @VUMCDiscoveries
3
5
29
1,515
Daniel Sur retweeted
I was challenged by @scserendipity1 at ESMO to share with him my favorite 8 song playlist with a few words of explanations. If you know him, you will also know that you just can’t ignore that request. 😂 I will thoroughly date myself with this but as I sometimes tell younger and much smarter and more accomplished colleagues, I have something on you that you can’t match. I grew up in the 80s. OK, here it comes… 1. Heaven knows I’m miserable now - The Smiths. This opened the indie music door for me I am ever since a die hard The Smiths fan. 2. ⁠That’s Entertainment- The Jam. The most perfect dysphoric 80s song there is. 3. ⁠In The Neighborhood- Tom Waits. The man (and his wife, Kathleen Brennan) just can’t do anything wrong. Seriously under appreciated artists. 4. ⁠Nous de la lune - Young Gods. Who doesn’t like Swiss industrial rock? Play it very loud. 5. ⁠Red right hand - Nick Cave and the Bad Seeds. Admittedly, I am a groupie… 6. ⁠Birthday - The Sugarcubes. My childhood next door neighbor I never dared to talk to. The most unique voice in rock. 7. ⁠Svefn-g-englar (transl. Sleepwalkers) - Sigur Rós One of the most unique and beautiful music videos there is. 8. ⁠Shine on you crazy diamond - Pink Floyd. Of course, one needs to know about Syd Barrett to fully understand. Not sure a better song about mental disorders and addiction has ever been written.
4
3
9
529
Well many of us are already using this schedule, nice to see a ph3 study that supports it.
Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial #ESMO26 #ESMOAmbassadors 👉ORR: 2 vs 2% 👉 mPFS: 3.9 vs 3.9 mo 👉 mOS: 10.3 vs 11.3 mo 🧐similar efficacy, less toxicity, supports biweekly schedule @myESMO @ASCO
5
13
365
Daniel Sur retweeted
🔥Presidential session at ESMO 2026 🔥 CLARITY-Gastric 01: Ph 3 of sonesitatug vedotin in 2L+ CLDN18.2-positive GEC #ESMO26 #ESMOAmbassadors 👉ORR: 23 vs 13% 👉mPFS: 4.2 vs 3.8 mo 👉mOS: 10 vs 5 mo 👉No new safety signals 🧐 exciting results, new option for 2L+ CLDN18.2+ pts @myESMO @ASCO
3
29
56
3,355
Daniel Sur retweeted
FOLFIRI plus ramucirumab vs paclitaxel plus ramucirumab as 2L therapy for taxane-pretreated patients with mGEA–Final results of the phase III IKFs602/AIO RAMIRIS Study #ESMO26 #ESMOAmbassadors 👉 ORR: 25 vs 23% 👉 mPFS: 5.5 vs 3.7 mo 👉 mOS: 8.7 vs 7.5 mo 🧐neg. study, but FOLFIRI + Ram appears reasonable option @myESMO @ASCO
14
17
872
🚨 ESMO 2026 | TOP 10 GI CANCER TRIALS TO WATCH! From CLDN18.2 ADCs and PD-1/VEGF bispecifics to chemotherapy-free strategies, major GI oncology data are coming at #ESMO26! 🔥 My Top 10 Trials 🔴 GASTRIC / GEJ CANCER CLARITY-Gastric 01 (LBA7) | CLDN18.2 ADC vs investigator’s choice G-HOPE-001 (LBA77) | Novel CLDN18.2 ADC HERIZON-GEA-01 (LBA79) | Zanidatamab + chemotherapy ± tislelizumab GERCOR-GONO DEWI | Dostarlimab and nonoperative management in dMMR disease LOMAC (LBA81) | 4 vs 6 months of adjuvant CAPOX KC-WISE (LBA80) | Anbenitamab + chemotherapy RAMIRIS | FOLFIRI + ramucirumab vs paclitaxel + ramucirumab FORTITUDE-101/102 | FGFR2-targeted therapy and biomarker analysis 🟠 BILIARY TRACT CANCER HARMONi-GI1 (LBA8) | Ivonescimab + chemotherapy vs durvalumab + chemotherapy 🟣 ESOPHAGEAL / GEJ CANCER KEYNOTE-975 (2875O) | Pembrolizumab + definitive chemoradiotherapy ⭐ Two Presidential trials to watch closely: CLARITY-Gastric 01 and HARMONi-GI1. Which GI trial will have the greatest clinical impact? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #GICancer #Oncology
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open
2
27
3
68
15,434
🇪🇸 Excellent Spanish-led review | GEA 🧬 Beyond PD-L1 & HER2 🧪 MSI-H | EBV | TMB | Immune signatures 🎯 CLDN18.2 | FGFR2b | MET 🚀 ADCs, bispecifics & cell therapies 👏 Great work by @tfleitask , @EduardoTB94 & M. Alsina! 🔗 doi.org/10.1016/j.esmogo.202… @OncoAlert
16
39
1,771
Dostarlimab (IV q3 wks, 9 cycles) is now @FDA ✅ for locally advanced (Stg II/III) MSI-H/dMMR rectal cancer off Ph II AZUR-1 study: - 71% got IO alone (no additional Rx) - Clinical CR for 12 mos: 47% (no progression at 26.3mos median f/u) - Surgery/Chemo free option! #gism
Replying to @AndreaCercek
@AndreaCercek 🤩announced at #ESMOGI2026 phase 2 AZUR-1 will be presented at @myESMO #ESMO2026 which was created to validate her original single center Dostarlimab data in #rectal #cancer. Looking forward to the results! #CancerResearch @GSK_US @OncoAlert
25
6
61
8,789
If you are a patient with a NET or a family member or a friend or just interested NET, please check this website out.
I'm pleased to announce the launch of NENfolk.org, a patient educational site focused on neuroendocrine neoplasms (NENs) and radiotheranostics. NENfolk aims to help patients and caregivers find credible content from reputable organizations, and in the formats that fit how they want to learn. Please check it out!
1
6
18
1,276
🏃‍♀️ CHALLENGE | ESMO Open Editorial 📈 5-y DFS +6.4% | 8-y OS +7.1% 🔎 38 fewer DFS events: ↘️ 42% recurrences 🧬 53% new primary cancers 💡 Exercise may prevent both colon cancer recurrence and second cancers. 🔗 doi.org/10.1016/j.esmoop.202… @OncoAlert @myESMO @GrupoTTD
11
19
1,700
Rare cancers are a critical model for all cancers. 🔥👉🫵✴️💡🦄Adopting the orphans requires the molecular reclassification of cancer. Cancers are N-of-1 unicorns: 2012 to 2026 pubmed.ncbi.nlm.nih.gov/4161…
1
7
1
44
2,626
I said good bye to Dr. Karan Sood at Logan Airport this afternoon as he heads back to Mumbai, India. The time he spent with us at @BrownUniversity and @BrownUnivHealth as a @WINConsortium Precision Oncology Fellow was productive and sets the stage for future work and collaboration. @Dr_R_Kurzrock @SewantiLimaye @LiaTsimberidou @VivekSubbiah @DrChoueiri @TataMemorial
3
4
1
23
1,503
Daniel Sur retweeted
Young-onset colorectal cancer is rising, and CRC demands focus. @MDAndersonNews has created a dedicated Department of Colorectal Medical Oncology to meet that challenge. Honored to serve as its inaugural Chair and partner with new GI Med Onc chair Arvind Dasari @adasarimd #CRCSM
26
35
5
208
8,126
Outstanding @WIN_Consortium international MTB in precision oncology this morning including challenging cases of CRC with KRAS and PIK3CA mutation, peritoneal carcinomatosis, MPNST with NF1, AXL, SUZ12, TP53 alterations among others, and recurring CRC over many years with WT KRAS, treated liver metastases, FANCA mutation now with brain metastases @Dr_R_Kurzrock @SewantiLimaye @bcarneiro7 @DrSGraff @JerryAzzoli @LiangChengMD @IAbuGheidaMD @alshamsi2000 @VivekSubbiah @DrRoyHerbst @DCarboneMD @jrgralow @billdahutmd @drKMusallam @LiaTsimberidou @RueterJens @LussierY
7
14
764
🧬 New ESMO Clinical Practice Guidelines | Gastric & oesophageal cancer 📚 Full patient journey: diagnosis → staging → treatment → follow-up 🧪 HER2 | MSI | CLDN18.2 | PD-L1 🎯 Recommendations tailored by stage, prior therapy & molecular profile 🔗 doi.org/10.1016/j.annonc.202… @OncoAlert
23
59
3,045
This is the future of oncology. Algorithm/AI-driven biomarker matching to unravel complexity
7
41
4,877
🤝An international collaboration with @aparna1024 and our CRC team @incliva_iis @GVAsanitat
12
24
1,523
🏃‍♀️ Exercise oncology | Nat Rev Clin Oncol 🔻 ↓ risk of several cancers 📉 ↓ cancer-specific/all-cause mortality after diagnosis ✅ CHALLENGE: ↑ DFS/OS in colon cancer ⚠️ No proven improvement in tumor response 🎯 Toward precision exercise oncology. 🔗 doi.org/10.1038/s41571-026-0… @OncoAlert
1
45
1
112
7,069
🚨⭐️HOT OFF THE PRESS👉Pleased to share our new paper, led by the amazing @JulianaRBeal @niamhjcoleman @JiaJennyLiu 👉Precision before incision: neoadjuvant tumor-agnostic therapies.” 👉Nine tumor-agnostic drugs now have a case for earlier use, before resistance sets in and with organ preservation in mind. 👉A PD-1 blockade hit a 100% complete response in MMR-deficient rectal cancer. 🧬 @JasonSicklick @OncoAlert @oncodaily cell.com/trends/cancer/abstr… #PrecisionOncology
5
20
2
57
4,118